Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Ultresa – Treatment for Exocrine Pancreatic Insufficiency (EPI)

Drug (Brand / Generic)

Ultresa / pancrelipase

Company / Licensee

Aptalis Pharma

Product Description

Pancreatic enzyme

Current Indication

Exocrine pancreatic insufficiency

Market Sector

Gastrointestinal

Development Status

Approved in US
Expand
Close
Close
Close

Go Top